Evofem Biosciences, Inc. is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health. Its primary product, PHEXX (lactic acid, citric acid and potassium bitartrate vaginal gel), is the first FDA-approved non-hormonal prescription contraceptive vaginal gel, launched in September 2020. The company also commercializes SOLOSEC (secnidazole 2g oral granules), a single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis, acquired in July 2024 and relaunched in November 2024.
PHEXX (lactic acid, citric acid and potassium bitartrate vaginal gel)
service
First and only FDA-approved non-hormonal prescription contraceptive vaginal gel, used 0-60 minutes prior to intercourse, launched in the U.S. in September 2020.
SOLOSEC (secnidazole 2g oral granules)
service
FDA-approved single-dose oral antimicrobial for treatment of bacterial vaginosis and trichomoniasis in patients 12 years of age and older.
Partnerships
Partner
Type
Description
Pharma 1 Drug Store, LLC
licensing
Licensed commercial rights to PHEXX (July 2024) and SOLOSEC (May 2025) in the MENA and GCC regions; Pharma 1 filed for UAE regulatory approval of PHEXX in June 2025 and SOLOSEC in September 2025.
Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking. AI Discovery Document | Registry Metrics | GitHub